Quantitative structure-activity relationships of antianginal drugs.
暂无分享,去创建一个
[1] J. Parratt,et al. The effect of adrenaline, noradrenaline, and propranolol on myocardial blood flow and metabolic heat production in monkeys and baboons. , 1969, Cardiovascular research.
[2] D. Langs,et al. Ca2+ channel ligands: Structure‐function relationships of the 1,4‐dihydropyridines , 1989, Medicinal research reviews.
[3] A. Martinelli,et al. Molecular orbital studies on the mechanism of drug-receptor interaction. 2. beta-Adrenergic drugs. An approach to explain the role of the aromatic moiety. , 1977, Journal of medicinal chemistry.
[4] L. H. Smith,et al. Beta-adrenergic blocking agents. 10. (3-amino-2-hydroxypropoxy)anilides. , 1971, Journal of medicinal chemistry.
[5] C. Hansch,et al. Comparative Quantitative Structure−Activity Relationship Studies on Anti-HIV Drugs , 1999 .
[6] M. Botta,et al. Pyrrolo[2,1-c][1,4]benzothiazines: synthesis, structure-activity relationships, molecular modeling studies, and cardiovascular activity. , 1995, Journal of medicinal chemistry.
[7] G. Gromo,et al. New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones. , 1995, Journal of medicinal chemistry.
[8] J. Tomasi,et al. Molecular orbital studies on the mechanism of drug-receptor interaction. 1. Adrenergic drugs. Conformation and reactivity of isoproterenol and 1-(p-nitrophenyl)-2-isopropylaminoethanol. , 1974, Journal of medicinal chemistry.
[9] D. Attwood,et al. The surface activity and self‐association of some β‐adrenoceptor blocking agents in aqueous solution , 1979, The Journal of pharmacy and pharmacology.
[10] M. Newman. Some Observations Concerning Steric Factors , 1950 .
[11] P. Needleman,et al. Relationship between glutathione-dependent dentration and the vasodilator effectiveness of organic nitrates. , 1969, The Journal of pharmacology and experimental therapeutics.
[12] M. Wasserman,et al. Selective beta adrenergic receptor blockade in the rat. , 1972, The Journal of pharmacology and experimental therapeutics.
[13] Satya P. Gupta,et al. QSAR studies on hallucinogens , 1983 .
[14] A M Triggle,et al. 1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach. , 1988, Journal of medicinal chemistry.
[15] S. Gupta. Quantitative structure-activity relationships of cardiotonic agents. , 2000, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[16] S. Gupta. QSAR studies on enzyme inhibitors , 1987 .
[17] M. Botta,et al. Diltiazem-like calcium entry blockers: a hypothesis of the receptor-binding site based on a comparative molecular field analysis model. , 1997, Journal of medicinal chemistry.
[18] G. M. Smith,et al. Diethyl 3,6-dihydro-2,4-dimethyl-2,6-methano-1,3-benzothiazocine-5,11- dicarboxylates as calcium entry antagonists: new conformationally restrained analogues of Hantzsch 1,4-dihydropyridines related to nitrendipine as probes for receptor-site conformation. , 1987, Journal of medicinal chemistry.
[19] C. Wermuth,et al. Synthesis and beta-adrenergic blocking activity of a novel class of aromatic oxime ethers. , 1977, Journal of medicinal chemistry.
[20] D. Triggle,et al. High affinity binding of a calcium channel antagonist to smooth and cardiac muscle. , 1982, Biochemical and biophysical research communications.
[21] A. M. Lands,et al. Differentiation of receptors responsive to isoproterenol. , 1967, Life sciences.
[22] S. P. Gupta,et al. QSAR studies on drugs acting at the central nervous system , 1989 .
[23] S. P. Gupta,et al. QSAR (quantitative structure-activity relationship) studies on local anesthetics , 1991 .
[24] A. Fleckenstein. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. , 1977, Annual review of pharmacology and toxicology.
[25] S. Gupta. Quantitative structure-activity relationships of antihypertensive agents. , 1999, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[26] C. Romming,et al. Crystal structures and pharmacological activity of calcium channel antagonists: 2,6-dimethyl-3,5-dicarbomethoxy-4-(unsubstituted, 2-methyl-, 4-methyl-, 3-nitro-, 4-nitro-, and 2,4-dinitrophenyl)-1,4-dihydropyridine. , 1982, Journal of medicinal chemistry.
[27] S. Moreland,et al. Studies directed toward ascertaining the active conformation of 1,4-dihydropyridine calcium entry blockers. , 1988, Journal of medicinal chemistry.
[28] Rongan Zhang,et al. Calcium entry blockers and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators. , 1995, Journal of medicinal chemistry.
[29] S. Unger. Consequences of the Hansch Paradigm for the Pharmaceutical Industry , 1980 .
[30] C. Hansch,et al. An analysis of the structure-activity relationship in the adrenergic blocking activity of the beta-haloalkylamines. , 1968, Biochemical pharmacology.
[31] S. Spergel,et al. 1-Benzazepin-2-one calcium channel blockers--VI. Receptor-binding model and possible relationship to desmethoxyverapamil. , 1993, Bioorganic & medicinal chemistry.
[32] J. B. Farmer,et al. Differentiation of β‐adrenoreceptors by the use of blocking agents , 1970 .
[33] J. V. Levy. Myocardial and local anesthetic actions of beta-adrenergic receptor blocking drugs: relationship to physicochemical properties. , 1968, European journal of pharmacology.
[34] A. Verloop,et al. Development and Application of New Steric Substituent Parameters in Drug Design , 1976 .
[35] P. Needleman,et al. Mechanism of tolerance development to organic nitrates. , 1973, The Journal of pharmacology and experimental therapeutics.
[36] J. V. Levy. Surface tension effects of β‐adrenergic blocking drugs , 1968 .
[37] Stefan H. Unger,et al. Model building in structure-activity relations. Reexamination of adrenergic blocking activity of .beta.-halo-.beta.-arylalkylamines , 1973 .
[38] J D GRAHAM,et al. STRUCTURE-ACTION RELATIONS IN N,N-DIMETHYL-2-HALO-GENOPHENETHYLAMINES. , 1963, Journal of medicinal chemistry.
[39] Y. Takahata,et al. Quantitative Structure-Activity Relationships for 1,4-Dihydropyridine Calcium Channel Antagonists (Nifedipine Analogues): A Quantum ChemicalKlassical Approach , 1994 .
[40] Triggle Dj. Calcium-channel antagonists: mechanisms of action, vascular selectivities, and clinical relevance. , 1992, Cleveland Clinic journal of medicine.
[41] R. Loutzenhiser,et al. Mechanisms of calcium antagonist-induced vasodilation. , 1983, Annual review of pharmacology and toxicology.
[42] A M Triggle,et al. Crystal structures of calcium channel antagonists: 2,6-dimethyl-3,5-dicarbomethoxy-4-[2-nitro-, 3-cyano-, 4-(dimethylamino)-, and 2,3,4,5,6-pentafluorophenyl]-1,4-dihydropyridine. , 1980, Journal of medicinal chemistry.
[43] A. M. Triggle,et al. Characterization of binding of the Ca++ channel antagonist, [3H]nitrendipine, to guinea-pig ileal smooth muscle. , 1983, The Journal of pharmacology and experimental therapeutics.
[44] Svante Wold,et al. Comparison Between X-Ray Crystallographic Data and Physicochemical Parameters with Respect to Their Information about the Calcium Channel Antagonist Activity of 4-Phenyl-1,4-dihydropyridines , 1986 .
[45] H. Grobecker,et al. Prediction of the non-specific cardiodepressant effects of beta-adrenoceptor blocking agents in vitro and in vivo by means of the Hansch analysis. , 1974, European journal of pharmacology.
[46] J. Parratt,et al. The effect of catecholamine infusions on myocardial blood flow, metabolic heat production and on general haemodynamics, before and after alprenolol (H56/28), in anaesthetized cats , 1970, British journal of pharmacology.
[47] D. J. Triggle,et al. New developments in calcium ion channel antagonists , 1983 .
[48] J. Pickett,et al. Gels in soap stabilized emulsions , 1976, The Journal of pharmacy and pharmacology.
[49] A Hedberg,et al. Active conformation of 1,4-dihydropyridine calcium entry blockers. Effect of size of 2-aryl substituent on rotameric equilibria and receptor binding. , 1991, Journal of medicinal chemistry.
[50] S. Goldmann,et al. 1,4‐Dihydropyridines: Effects of Chirality and Conformation on the Calcium Antagonist and Calcium Agonist Activities , 1991 .
[51] S. Gupta. Quantitative Structure-Activity Relationship Studies on Anticancer Drugs , 1994 .
[52] Hans-Dieter Höltje,et al. A molecular graphics study on structure-action relationships of calcium-antagonistic and agonistic 1,4-dihydropyridines , 1987, J. Comput. Aided Mol. Des..
[53] H. A. Germer. A molecular orbital study of tissue selectivity in ß‐adrenoceptor blocking agents , 1974, The Journal of pharmacy and pharmacology.
[54] M. Bristow,et al. Analysis of beta receptor drug interactions in isolated rabbit atrium, aorta, stomach and trachea. , 1970, The Journal of pharmacology and experimental therapeutics.
[55] A. M. Lands,et al. Differentiation of Receptor Systems activated by Sympathomimetic Amines , 1967, Nature.
[56] W G Richards,et al. QSAR of binding of dihydropyridine‐type calcium antagonists to their receptor on ileal smooth muscle preparations , 1986, The Journal of pharmacy and pharmacology.
[57] S. Snyder,et al. Calcium antagonists receptor sites labeled with [3H]nitrendipine , 1982 .
[58] A. Cammarata,et al. Interrelationship of the regression models used for structure-activity analyses. , 1972, Journal of medicinal chemistry.